国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2010年
11期
845-848
,共4页
头颈部肿瘤%抗体,单克隆%受体,表皮生长因子
頭頸部腫瘤%抗體,單剋隆%受體,錶皮生長因子
두경부종류%항체,단극륭%수체,표피생장인자
Head and neck neoplasm%Antibodies,monoclonal%Receptor,epidermal growth factor
近十年中,靶向治疗逐渐成为头颈部综合治疗策略中重要的组成部分.靶向药物包括各种单克隆抗体、小分子化合物以及反义寡核苷酸等.西妥昔单抗是目前唯一获得批准用于头颈部癌治疗的靶向药物,其他靶向药物如吉非替尼、拉帕替尼等在头颈部癌的Ⅰ～Ⅲ期临床试验中亦获得令人鼓舞的结果.
近十年中,靶嚮治療逐漸成為頭頸部綜閤治療策略中重要的組成部分.靶嚮藥物包括各種單剋隆抗體、小分子化閤物以及反義寡覈苷痠等.西妥昔單抗是目前唯一穫得批準用于頭頸部癌治療的靶嚮藥物,其他靶嚮藥物如吉非替尼、拉帕替尼等在頭頸部癌的Ⅰ～Ⅲ期臨床試驗中亦穫得令人鼓舞的結果.
근십년중,파향치료축점성위두경부종합치료책략중중요적조성부분.파향약물포괄각충단극륭항체、소분자화합물이급반의과핵감산등.서타석단항시목전유일획득비준용우두경부암치료적파향약물,기타파향약물여길비체니、랍파체니등재두경부암적Ⅰ～Ⅲ기림상시험중역획득령인고무적결과.
Toxicity has impeded the advance of chemoradiotherapy for head and neck cancer, while targeted therapy has demonstrated some advantage. Over the past decade, targeted therapy is becoming the important section in multimodal approaches for head and neck cancer. Targeted drugs include monoclonal antibodies, small molecular chemicals and antisense oligodeoxynucleotide, etc. Cetuximab is the only targeted agent approved for this malignancy, and other targeted drugs, such as gefitinib and lapatinib, have demonstrated encouraging outcome in phase Ⅰ -Ⅲ clinical trials for head and neck cancer.
